Result: M204V/I: 48.8%, plus L180M: 33.3% +- L80V: 28.8% and V173L: 42.2%:a profile suggestive for LAM resistance (with all mutations, except for M204V, also being associated with telbivudine resistance, and the combination of L180M, M204V, andV173L being associated with entecavir (ETV) resistance.
Discussion: In our study, despite the frequent association of the primary resistance mutations M204V/I with the compensatory L180M, V173L, and L80V/I mutations, lamivudine-resistant HBV strains tend to be associated with lower viral loads compared to wild-type strains; further characterization of t
Hepatitis B virus genetic multiplicity and the associated HBV lamivudine resistance mutations in HBV/HIV co-infection in Western Kenya: A review article.
PMID: 34954390
2022
Infection, genetics and evolution
Abstract: HBV polymerase rtV173L, rtL180M, and rtM204V major substitutional mutations were identified.
Dried blood spot sampling for hepatitis B virus quantification, sequencing and mutation detection.
Abstract: An HIV-coinfected patient presented the rtM204V/I-rtL180M double resistance mutation in serum and DBS.
Result: One patient had the double resistance polymerase mutation rtM204V/I-rtL180M, in both serum and DBS.
Table:
Discussion: Regarding resistance mutations, the double rtM204V/I-rtL180M mutation in polymerase gene (to lamivudine, telbivudine and entecavir:partial) was observed in both serum and DBS samples from an HIV-treated patient.
Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient.
Result: HBV RT rtL180M and rtM204V Mutations Are Associated with BFV Resistance.
Result: Since the previous reports showed that two mutations (rtL180M or rtM204V) are associated with resistance to NA drugs such as LMV and ETV, the MVLIM mutant clone were divided into four distinct clones (LIM, MV, M, and V) to further screen the mutation that is responsible for BFV resistance.
Result: Taken together, these observations indicated that rtL180M and/or rtM204V substitution contributed to development of BFV resistance.
Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy.
Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro.
Introduction: In contrast, the HBV variant with three mutations in the polymerase gene (rtV173L + rtL180M + rtM204V), also generating the G145R mutation in S-HBsAg due to overlapping reading frames, was stable.
High Prevalence of Preexisting HBV Polymerase Mutations in Pregnant Women Does Not Limit the Antiviral Therapy Efficacy.
PMID: 33986897
2021
The Canadian journal of infectious diseases & medical microbiology
Result: However, rtI169 T, rtA194 T, rtV173 L, rtL180 M, rtL82 M, rtS85 A, rtV207I, rtL217 R, and rtS/C256G mutations were not present before TBV treatment.
Entecavir resistance in a patient with treatment-naive HBV: A case report.
PMID: 33903819
2021
Molecular and clinical oncology
Introduction: In fact, resistance to ETV appears to occur through a two-hit mechanism with primary LVD resistance (LVDr) substitutions (M204V/I with/without rtL180M) followed by amino acid substitutions at the rtI169, rtT184, rtS202 or rtM250 sites.
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
Result: L180M and M204I/V were both present in all genotypes and continents that we analysed (Figure 1B, C).
Result: However, four sequences (KF214668, KF214671, KF214673 and KF214676) with RAM I269L and one sequence (KF214659) with VEM S/T143M were sampled from Asia in 1963, and one sequence (HQ700441) with RAM L180M was sampled from Oceania in 1984, demonstrating that relevant mutations can arise without exposure to treatment or vaccination.
Result: RAMs L80I/M/V, V173L, L180M, A181T/V and T184X are common to 3TC, ETV and/or TFV.
Result: Some sequences containing both
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.
Abstract: Four mutations (rtS106C, rtD134N/S[N/S], rtM204V, and rtL269I) plus ETV resistance (rtL180M and rtS202G) existed when she developed viral breakthrough during ETV and TDF combination therapy in April 2013.
Abstract: In conclusion, three mutations (CN/SI) plus ETV resistance (rtL180M, rtM204V, and rtS202G) can cause tenofovir resistance.
HBV mutation literature information.
PMID: 
2022
Medicina (Kaunas, Lithuania)
Browser Board
Co-occurred Entities
Filtrator
ViMRT